Lapatinib in breast cancer: clinical experiences and future perspectives

被引：17
|
作者：
Giampaglia, M. [1 ]
Chiuri, V. E.
Tinelli, A. [2 ]
De Laurentiis, M. [3 ,4 ]
Silvestris, N. [5 ]
Lorusso, V.
机构：
[1] Osped Vito Fazzi, Med Oncol Unit, UO Oncologia Med, I-73100 Lecce, Italy
[2] Osped Vito Fazzi, Dept Obstet & Gynaecol, I-73100 Lecce, Italy
[3] Natl Canc Intitute Fdn Pascale, Dept Breast Oncol, Naples, Italy
[4] Univ Naples Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
[5] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
Breast cancer; EGFR; HER2; Lapatinib; Trastuzumab; Anthracycline; Taxane; Chemotherapy; Tyrosine-kinase inhibitor; DUAL KINASE INHIBITOR; PHASE-II TRIAL; BRAIN METASTASES; GW572016; LAPATINIB; BIOMARKER PROFILES; TYROSINE KINASES; PLUS TRASTUZUMAB; DOSE-ESCALATION; OPEN-LABEL; COMBINATION;
D O I：
10.1016/S0305-7372(10)70024-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after chemotherapy regimens containing anthracycline, taxanes and trastuzumab. Moreover, lapatinib is under investigation in combination with anthracycline and taxanes in neoadjuvant and adjuvant settings. Another potential field of investigation for this drug is related to its ability to restore hormonal sensitivity of HER2-, hormone-receptor positive breast cancer cells. This paper reviews the current use of lapatinib in breast cancer and its future perspectives. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：S72 / S79
页数：8
相关论文
共 50 条
  • [1] Lapatinib: Current status and future directions in breast cancer
    Moy, Beverly
    Goss, Paul E.
    [J]. ONCOLOGIST, 2006, 11 (10): : 1047 - 1057
  • [2] Lapatinib and breast cancer: current indications and outlook for the future
    Moreira, Cynthia
    Kaklamani, Virginia
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (08) : 1171 - 1182
  • [3] Lapatinib in breast cancer
    Bilancia, D.
    Rosati, G.
    Dinota, A.
    Germano, D.
    Romano, R.
    Manzione, L.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 26 - 30
  • [4] Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives
    Grant, Stephen G.
    Melan, Melissa A.
    Latimer, Jean J.
    Witt-Enderby, Paula A.
    [J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2009, 11
  • [5] Cancer therapeutics - Personal experiences and future perspectives
    Mihich, E
    [J]. CANCER BIOLOGY & THERAPY, 2004, 3 (09) : 911 - 915
  • [6] The future perspectives of breast cancer therapy
    Cho, L. W. C.
    Yiu, C. C. P.
    Yip, A. Y. S.
    Loo, W. T. Y.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (06) : 259 - 262
  • [7] Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    Mukherjee, A.
    Dhadda, A. S.
    Shehata, M.
    Chan, Stephen
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2189 - 2204
  • [8] Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
    Ades, Felipe
    Zardavas, Dimitrios
    Bozovic-Spasojevic, Ivana
    Pugliano, Lina
    Fumagalli, Debora
    de Azambuja, Evandro
    Viale, Giuseppe
    Sotiriou, Christos
    Piccart, Martine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2794 - +
  • [9] The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives
    D'Amico, Paolo
    Corvaja, Carla
    Gerratana, Lorenzo
    Reduzzi, Carolina
    Curigliano, Giuseppe
    Cristofanilli, Massimo
    [J]. JOURNAL OF CANCER METASTASIS AND TREATMENT, 2021, 7
  • [10] Lapatinib in the treatment of breast cancer
    Higa, Gerald M.
    Abraham, Jame
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (09) : 1183 - 1192
12345